# A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer

> **NCT07750041** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **CSPC Megalith Biopharmaceutical Co.,Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Unresectable Advanced or Metastatic Colorectal Cancer

## Interventions

- **DRUG:** SYS6090 (Fixed Dose Level A) + bevacizumab
- **DRUG:** SYS6090 (Fixed Dose Level B ) + bevacizumab
- **DRUG:** SYS6090 RP2D + bevacizumab +mFOLFOX6
- **DRUG:** SYS6090 RP2D + bevacizumab
- **DRUG:** Regorafenib
- **DRUG:** SYS6090 PR2D+ bevacizumab + FOLFOXIRI
- **DRUG:** bevacizumab + FOLFOXIRI

## Key facts

- **NCT ID:** NCT07750041
- **Lead sponsor:** CSPC Megalith Biopharmaceutical Co.,Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2029-08-30
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07750041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07750041, "A Phase Ib/II Study of SYS6090 Combination Therapy in Advanced Colorectal Cancer". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07750041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*